Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws
NEW YORK, Nov. 13, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NasdaqGM: SRPT) for possible breaches of fiduciary duty.
Click here to learn more about the investigation: http://zlk.9nl.com/sarepta-srpt/ or call: 877-363-5972. There is no cost or obligation to you.
On November 11, 2013, the Company announced that it had been instructed by the Food and Drug Administration not to file for accelerated approval of eteplirsen, the Company's drug to treat Duchenne muscular dystrophy. Sarepta shares fell more than 64% upon this news.
If you own Sarepta stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/sarepta-srpt/.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510
SOURCE Levi & Korsinsky, LLP